Reduced cortical thickness in right Heschl’s gyrus associated with auditory verbal hallucinations severity in first-episode schizophrenia

Xudong Chen¹, Shengxiang Liang², Weidan Pu³, Yinnan Song², Tumbwene E. Mwansisya¹,4, Qing Yang⁵, Haihong Liu⁶, Zhening Liu¹, Baoci Shan² and Zhimin Xue¹*

Abstract

Background: Auditory verbal hallucinations (AVHs) represent one of the most intriguing phenomena in schizophrenia, however, brain abnormalities underlying AVHs remain unclear. The present study examined the association between cortical thickness and AVHs in first-episode schizophrenia.

Method: High-resolution MR images were obtained in 49 first-episode schizophrenia (FES) patients and 50 well-matched healthy controls (HCs). Among the FES patients, 18 suffered persistent AVHs (“auditory hallucination” AH group), and 31 never experienced AVHs (“no hallucination” NH group). The severity of AVHs was rated by the Auditory Hallucinations Rating Scale (AHRS). Cortical thickness differences among the three groups and their association with AVHs severity were examined.

Results: Compared to both HCs and NH patients, AH patients showed lower cortical thickness in the right Heschl’s gyrus. The degree of reduction in the cortical thickness was correlated with AVH severity in the AH patients.

Conclusions: Abnormalities of cortical thickness in the Heschl’s gyrus may be a physiological factor underlying auditory verbal hallucinations in schizophrenia.

Keywords: Schizophrenia, Auditory hallucination, Cortical thickness, Magnetic resonance imaging, Heschl’s gyrus

Background

Schizophrenia is one of the most debilitating mental illnesses [1], characterized by positive symptoms, negative symptoms and cognitive deficits. As a core positive symptom, auditory verbal hallucinations (AVHs) is an important diagnostic criterion for schizophrenia [2], which has been shown to be closely related to schizophrenia patients’ long-term social functioning and quality of life [3].

Previous neuroimaging studies have revealed widespread morphological abnormalities associated with AVHs, such as gray matter loss in the frontal [4, 5], insular [6], and anterior/posterior cingulate [7, 8] cortices. The most extensively focused brain region in the investigation of AVHs is the temporal lobe, in particular the primary auditory cortex (PAC, also known as Heschl’s gyrus), and the secondary auditory cortex [9]. Both are known to be crucial for auditory perception and comprehension [10]. Several lines of evidence have shown that schizophrenia patients with AVHs present reduced gray matter volumes in the superior and transverse temporal gyri [11–13]. Furthermore, a recent meta-analysis of voxel-based morphometry (VBM) studies included a large sample totaling 438 patients (307 with AVHs) and confirmed a significant correlation between the extent of gray matter loss in the Heschl’s gyrus (HG) and the severity of AVHs [14]. Interestingly, by applying a manual segmentation method, another study found that hallucinating patients exhibited increased volume in the HG [15]. Yet another study found that schizophrenia patients with AVHs had increased...
volumes of temporal gray and white matter compared to patients without AVHs [4]. The inconsistent findings may be accounted for by differences in methodology [14], hallucination history [16], symptom diversity [17], substance abuse [18], illness course [19, 20], and antipsychotic medication use [21]. Thus, controlling potentially confounding factors listed above may help provide more reliable evidence on the alternations in brain structures underpinning AVHs.

In the present study, we recruited two groups of first-episode schizophrenia patients, who were carefully matched for socio-demographic variables, illness course, medication dose, and symptom severity (except for the AVHs). The auditory hallucination (AH) group included patient with current and persistent AVHs. Patients without current hallucinations or with only occasional hallucinations based on the Scale for Assessment of Positive Symptoms (SAPS) were excluded. In the no hallucination (NH) group, patients with any AVH history were excluded. (For detailed inclusion and exclusion criteria, please see Methods). Furthermore, a group of healthy controls (HCs) was also recruited, matching the patients in age, sex and years of education.

By applying a novel surface-based analysis approach to the matched schizophrenia patient samples, we aimed at characterizing the cortical thickness in the first-episode schizophrenia patients with and without AVHs. We expected patients with AVHs to show altered cortical thickness correlating with their AVH severity.

Methods

Study subjects

Forty-nine right-handed first-episode schizophrenia (FES) patients who were diagnosed with schizophrenia within the past 18 months with no previous episodes of psychosis as per Diagnostic and Statistical Manual for Mental Disorders Fourth Edition (DSM-IV), determined by the Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-I/P) [22], were recruited from an inpatient unit at the Second Xiangya Hospital of Central South University, Changsha. Inclusion criteria for both patients and healthy controls were similar: (1) age between 18 and 45 years old; (2) Han Chinese; and (3) sufficient understanding and expressive capacity with >9 years of education. Exclusion criteria for participants were: (1) moderate to severe learning disability; (2) a history of substance abuse; (3) a history of brain trauma or neurological disease; (4) left-handedness; and (5) previous electroconvulsive therapy and any other contraindications to MRI. Diagnosis of schizophrenia and the symptom ratings were determined by the consensus of two experienced psychiatrists (Z.L. and H.L.). The hallucination history was determined based on the SCID-I/P hallucinations items. Of the patients with first-episode schizophrenia, 18 suffered persistent AVHs and were classified as the auditory verbal hallucinations group (AH). In particular, patients were assigned to the AH group if they scored >2 on item 2 or 3 of the SAPS and patients with occasional hallucinations were excluded (hallucinations score = 2). The other 31 patients with first-episode schizophrenia had never experienced auditory verbal hallucinations (no hallucinations group, NH).

Fifty right-handed healthy controls (HCs) were recruited from the city of Changsha through poster advertisements and screened. HCs were evaluated using the SCID-Non-Patient Edition to confirm the lifetime absence of psychiatric and neurological illnesses [23]. HCs who met the DSM-IV criteria for an Axis-I psychiatric disorder were excluded. Additionally, healthy subjects were interviewed to confirm that there was no history of psychiatric illnesses among their first-degree relatives. The Ethics Committee at Second Xiangya Hospital of Central South University reviewed and approved the study. All participants received a description of the experimental procedures and gave written informed consent to participate in the study.

Participants’ IQ was estimated using the information subscale and digit-symbol coding subscale of the Wechsler Adult Intelligence Scale (WAIS)-Chinese version [24]. In subjects with schizophrenia, positive and negative symptoms within 1 month prior to the study were assessed using the Scale for Assessment of Positive Symptoms (SAPS) [25] and the Scale for the Assessment of Negative Symptoms (SANS) [26], respectively. AVH severity was evaluated using the Auditory Hallucinations Rating Scale (AHRs). This questionnaire assesses multiple characteristics of AVHs, such as the frequency of occurrence, length of episodes, loudness of the voices, and influence and discomfort of AVHs as experienced by the patient [27]. Dosage of antipsychotic medication equivalent to 100 mg/day of chlorpromazine (CPZ) was also calculated [28]. Handedness was ascertained using the Annett Hand Preference Questionnaire [29].

To minimize the effects of chronicity of illness and neuroleptic medications on brain structure, this study preferentially recruited patients who were just beginning treatment with antipsychotic medication for the first time and matched the medication dose between the two patient groups. Current and previous antipsychotic regimens (medication and duration of use) were recorded. In the patient groups, two patients (4 %) never received antipsychotic treatment, 43 patients had been on antipsychotic treatment for less than 4 weeks and four patients had been treated for more than 4 weeks. One patient (2 %) was receiving first-generation antipsychotics (FGAs) monotherapy (sulpiride, 1 case); 41 patients (84 %) were receiving second-generation antipsychotics (SGAs) monotherapy (clozapine, 1 case; risperidone, 19 cases; quetiapine, 2 cases; olanzapine, 15 cases; aripiprazole, 1 case;
ziprasidone, 3 cases) and five patients (10%) were receiving combination antipsychotic therapy (combining an SGA and an SGA). Mean current treatment duration was 11.92 (SD = 13.52) days and mean lifetime exposure to antipsychotics was 13.06 (SD = 14.95) days among the 49 patients.

**Magnetic resonance imaging acquisition**

High-resolution T1-weighted images were acquired using T1-weighted 3D turbo field echo (T1W-3D-TFE) on a 3.0-Tesla Philips Achieva MRI scanner (Philips, The Netherlands) with the following parameters: repetition time = 7.5 ms, echo time = 3.7 ms, flip angle = 8°, field of view = 240 × 240 mm², acquisition matrix = 256 × 200, slice thickness = 1 mm, gap = 0, number of slices = 180. Foam pads and earplugs were used to minimize head motion and scanner noise. All scans were inspected for motion artifacts. The absence of gross pathological findings was confirmed by a neuroradiologist. All patients and controls were examined during the same study period and there was no scanner upgrade during this time.

**Cortical thickness measurement and cortical parcellation**

Images were processed and cortical thickness was measured using the longitudinal stream in FreeSurfer version 5.2.0 (http://surfer.nmr.mgh.harvard.edu/fswiki/recon-all/), which has been validated in previous research [30]. All the processing steps, including motion correction, skull stripping, registration to Talairach space, intensity normalization, segmentation of the white matter and gray matter, tessellation of the gray-white boundary, automatic topology correction and surface deformation, were completed using the fully automated pipeline without any manual intervention. Cortical thickness was calculated as the average of the closest distance from the white matter to the vertex and the closest distance from the vertex to the white matter [31]. The cortex of each hemisphere was automatically parcellated into 34 regions (based on [32], available from http://surfer.nmr.mgh.harvard.edu/fswiki/CorticalParcellation), subdividing the human cerebral cortex into standard gyral neuroanatomical regions. This highly reliable parcellation method has been adopted in a line of previous studies [33, 34]. The average cortical thickness of each region from both FES patients and HCs were extracted. All results of cortical parcellations were examined by both visual inspection and FreeSurfer QA Tools (available from http://www.freesurfer.net/fswiki/QATools).

**Statistics**

Statistical analysis was performed with Statistical Package for Social Sciences, version 17.0 (SPSS Inc., Chicago, Illinois). Differences in age and educational levels among the three groups were assessed using Analyses of Variance (ANOVA). Gender differences were compared using the chi-squared test. The average cortical thickness in the 34 regions of each hemisphere was extracted and entered into SPSS software using a general linear model and compared among the patient groups and healthy controls, with age and sex serving as covariates. Significance was set to p < .05, corrected for multiple comparisons using Least Significant Difference (LSD).

Pearson correlation analysis was performed on the average cortical thickness in regions with altered thickness and the AHRS scores, and the total score of the SAPS and SANS to examine potential associations between anatomical deficits and clinical symptoms. Furthermore, we used Pearson correlation to quantify the relationship between the duration of illness and the alterations in cortical thickness. P < .05 was considered significant. Additionally, given that the CPZ equivalent of current medication dose did not follow a normal distribution, Spearman’s rank correlation analysis between cortical thickness and medication dose was performed.

**Results**

**Demographic and clinical characteristics**

Demographic and clinical characteristics of the groups are shown in Table 1. There were no significant differences among the groups regarding age, sex, and years of education. No difference emerged with respect to the duration of illness or medication dosage between the AH and NH patient groups. Relative to the NH patients, the AH patients scored significantly higher on total SAPS score, but not for total SAPS score minus hallucinations subscales or total SANS score. In addition, there was no significant difference between the two patient groups in any of the sub-scores of SANS or SAPS except for hallucinations (see Table 1).

**Alterations in patient cortical thickness**

Group ANCOVA analysis demonstrated that only the right transverse temporal cortex (Heschl’s gyrus) showed significant difference in cortical thickness among the three groups (F = 6.06 p < .05; see Table 2 and Additional file 1: Table S1). Post-hoc comparisons showed that the right HG cortical thickness was significantly reduced in the AH patients compared to that of the NH patients as well as the HCs (p < .05, corrected for multiple comparisons with LSD; see Table 2, Fig. 1).

**Correlation between alterations in cortical thickness and clinical symptoms severity**

In the AH group, the average cortical thickness of the region with reduced cortical thickness (i.e., right HG) negatively related to the severity of AVHs, as assessed by
Table 1 Demographic and clinical characteristics of participants

| Demographics                        | AH (n = 18) | NH (n = 31) | HC (n = 50) | Chi-Square Analysis/t tests |
|-------------------------------------|-------------|-------------|-------------|---------------------------|
| Age, years                          | 24.11(6.27) | 24.29(5.92) | 24.98(6.60) | F = .18 .835             |
| Sex, (% male)                       | 12(66.67 %) | 17(54.80 %) | 25(50.00 %) | \(\chi^2 = 1.48 \) .479 |
| Education, years                    | 12.42(2.92) | 12.50(2.22) | 13.2(2.16)  | F = 1.22 .299            |
| Duration of illness, months         | 6.33(4.78)  | 7.09(4.48)  |             | t = − .56 .579          |
| WAIS-Information                    | 17.89(6.07) | 16.31(4.42) | 20.22(4.50) | F = − 3.32 .002* NH < HC |
| WAIS-Digit symbol                   | 66.00(16.97)| 68.00(15.61)| 86.56(16.01)| F = − 6.14 < .001* AH, NH < HC |

Clinical Variables

AHRS

|                                      | AHRS        |
|--------------------------------------|-------------|
| Global rating of Hallucinations     | 2.78(1.93)  |
| Global rating of Delusions          | 2.27(1.45)  |
| Global rating of Bizarre Behaviour   | .56(1.20)   |
| Global rating of Positive Formal Thought Disorder | .83(1.25) |
| Total                                | 27.78(14.65)|
| Total – Hallucinations              | 14.89(10.82)|

SANS

|                                      | SANS        |
|--------------------------------------|-------------|
| Global Rating of Affective Flattening| 1.06(1.21)  |
| Global Rating of Alogia              | 0.83(1.20)  |
| Global Rating of Avolition - Apathy  | 1.28(1.23)  |
| Global Rating of Anhedonia- Asociality| 1.67(1.33) |
| Global Rating of Attention           | 0.83(0.92)  |
| Total                                | 21.44(19.92)|
| Chlorpromazine equivalents (mg)      | 189.35(62.09)|

*\(p < .05\)

HC healthy controls, AH hallucinating patients with schizophrenia, NH non-hallucinating patients with schizophrenia, Total-Hallucinations total SANS score minus hallucinations subscales score

AHRS Auditory Hallucinations Rating Scale, SANS Scale for the Assessment of Negative Symptoms, WAIS Wechsler Abbreviated Scale of Intelligence

\*Mean and SD are reported unless otherwise specified. Analyses of demographics and clinical data were performed in SPSS (http://www.spss.com). All tests were two-tailed

\(b\)Age was defined as age at the time of magnetic resonance imaging scanning

\(c\)Years of education refers to the total number of years of completed education as reported by the participant

\(d\)Duration of illness was defined as number of years between age at onset and age at MRI scanning

Table 2 Cortical thickness of schizophrenia patients and healthy controls in right Heschl’s gyrus

| Cortical thickness(mm) | ANCOVA | Pairwise comparisons* |
|------------------------|--------|-----------------------|
|                        | Mean   | SD        | F      | P values | Mean difference | P values |
| AH                     | 2.99   | .25       |        |         | -1.161          | .021*    |
| NH                     | 3.16   | .22       | 6.06   | .003**  | .062             | .246     |
| HC                     | 3.21   | .27       |        |         | -2.233           | .001*    |

*\(p < .05\), **\(p < .01\)

HC healthy controls, AH hallucinating patients with schizophrenia, NH non-hallucinating patients with schizophrenia

*Adjustment for multiple comparisons: Least Significant Difference
AHRS scores, but not with SAPS or SANS (see Fig. 1). Greater reduction in the cortical thickness was observed in patients with more severe AVHs. No significant correlation was observed between the cortical thickness in the region with altered thickness and the duration of illness ($r = -0.22$, $p > 0.05$), or the medication dosage in the patient groups ($r = 0.14$, $p > 0.05$).

**Discussion**

In line with our hypothesis, we found that reduced cortical thickness in Heschl’s gyrus was significantly related to auditory hallucinations in FES patients. One advantage of the present study, which specifically isolated patients with current and persistent auditory hallucinations and compared them with matched non-hallucinating patients and healthy controls, is phenotypic homogeneity to explore the neural correlates of hallucinations. Notably, our patient groups differed only in terms of AVH symptomatology, minimizing the confounding effect of other clinical characteristics.

Several advantages of this study, particularly on the controlling confounding factors, are of strong interest for identifying the specific anatomical deficits associated with verbal hallucinations. First, excessive cortex thinning over time in the frontal and temporal areas has been demonstrated in schizophrenia and the changes can progresses across the entire course of the illness [35]. We recruited patients with first-episode schizophrenia with relatively short illness duration to minimize confounding effects of the chronic illness course on the neural substrate of hallucination. Second, association between psychotic symptoms and different deficits in cortical thickness has been observed [36]. Moreover, it has been indicated that antipsychotic drugs affect the regional cerebral volume, particularly in the frontal lobes [37, 38] and caudate nucleus [39]. Therefore, we matched the symptoms severity (other than hallucinations) and medication dosage between the two patient groups, further facilitating the identification of specific neuro-substrate of hallucinations. Finally, we used the surface-based cortical thickness approach, which can acquire data at the sub-
voxel resolution [40], reflecting the size, density, and arrangement of neurons, glial cells, and synaptic spines [41]. Given that surface-based methods are designed to remove individual variability in local cortical folding [31], the cortical thickness might elucidate the exact nature of potential structural alterations in schizophrenia.

The Heschl’s gyrus belongs to the primary auditory cortex [42], which is surrounded by the secondary auditory processing areas on the superior temporal gyrus (STG). Our findings are consistent with a recent meta-analysis of voxel-based morphometry study [14], which revealed that the severity of AVHs was significantly associated with gray matter volume (GMV) reductions in bilateral HG and STGs. HG structural abnormalities has been reported to relate with the severity of auditory hallucinations [13], which is also replicated in our study. In adolescent schizophrenia patients [43], gray and white matter volume reduction in the HG has been observed. Furthermore, cortical thinning in the HG was reported in both high-risk neonates and adults with schizophrenia [34, 44], suggesting that the HG structural abnormalities may relate to genetic predispositions.

Previous studies also reported structural abnormalities in other brain regions, such as frontal [4, 5], temporal [9] and insular cortex [6], whereas we did not observe any difference in cortical thickness in these areas. Such contradictory findings may be attributed to differences of methodology and schizophrenia heterogeneity. First, in contrast to our surface-based morphometry analysis, most previous studies applied the voxel-based morphometry (VBM) approach. The VBM approach mainly focuses on the structural changes in the gray matter volume or density, not cortical thickness. To the best of our acknowledge, there has been only one previously published study assessing cortical thickness in a relatively small sample of 10 chronically hallucinating schizophrenic patients, which found cortical thickness increase in the parahippocampal gyrus and reduction in the frontal and temporal cortex [45]. Schizophrenia is a very heterogeneous mental disorder. Patients present with a variety of clinical symptoms and durations of illness. Different from that study, all patients in our study were in their first-episode (mean duration of illness 6.8 months). Evidence has demonstrated that schizophrenia patients show cortex thinning over time across the entire course of illness [35], suggesting that the chronicity of the illness might be an important contributor to cortical thinning. Moreover, in the present study, we did not observe significant thickness reduction in the left HG. This finding concurs with previous studies demonstrating that in the primary auditory cortex, the morphometric changes appeared to be more consistent on the right than the left in schizophrenia patients [46, 47].

Although the underlying neuropathology of the HG gray matter reduction is not clear, postmortem studies have suggested that cortical thinning may reflect a loss of neuropil or altered pruning [48, 49]. Based on the knowledge of previous studies and our results, the anatomical deficits in the primary auditory cortex may represent a core pathology of AVHs during the early course of schizophrenia.

This study has some limitations. First, the FES patients included in the study were not completely treatment-naïve; most of them had received a relatively short course of antipsychotic medications. Studies showed that long term antipsychotic medication has a significant impact on brain morphology [50]. However, the two patient groups here did not differ in terms of medication dosage or duration. In addition, when we further controlled for medication effects by performing correlation analysis with CPZ-equivalents in patient groups, and there was no significant correlation between CPZ-equivalent and cortical thickness. Second, our analysis method only allowed inference on cortical thickness alterations. Due to the limitations associated with the MRI structural measurements, the effects of vascularization and tissue fluid levels cannot be excluded. Third, although the total FES group is reasonably large, the power of the study might be limited by dividing patients into subgroups with and without AVHs. Given the cross-sectional nature of this study, we cannot exclude a potential impact of schizophrenia heterogeneity on our findings and future longitudinal studies are warranted to better understand the developmental context of these structural alterations in patients with auditory hallucinations.

Conclusion

In conclusion, the present study demonstrated that first-episode schizophrenia patients with AVHs exhibit reduced cortical thickness in the right HG that was associated with severity of auditory hallucinations. This finding suggests that anatomical deficits in primary auditory cortex gyrus may modulate the pathogenesis of auditory verbal hallucinations in the early stage of schizophrenia.

Additional file

Additional file 1: Table S1. Regional cortical thickness of schizophrenia patients and healthy controls.

Abbreviations

AVHs: Auditory verbal hallucinations; HCs: Healthy controls; FES: First-episode schizophrenia; AHRS: Auditory Hallucinations Rating Scale; AH: Auditory hallucination; NH: No hallucination; PAC: Primary auditory cortex; VBM: Voxel-based morphometry; HG: Heschl’s gyrus; SAPS: Scale for Assessment of Positive Symptoms; SANS: Scale for the Assessment of Negative Symptoms; DSM-IV: Diagnostic and Statistical Manual for Mental Disorders Fourth Edition; SCID-I/P: Structured Clinical Interview for DSM-IV Axis I Disorders.
References

1. Insel TR. Rethinking schizophrenia. Nature. 2010;468(7321):187–93.
2. APA. Diagnostic and statistical manual of mental disorders DSM-IV-TR. 4th edn. (Text Revision). Washington, DC: American Psychiatric Publishing, Inc. 2000.
3. Hoffman RE. Auditory/Verbal hallucinations, speech perception, and the social deaffrentation hypothesis. Clin EEG Neurosci. 2008;39(2):87–90.
4. Shin SE, Lee JS, Kang MH, Kim CE, Bae JN, Jung G. Segmental volumes of cerebrum and cerebelum in first episode schizophrenia with auditory hallucinations. Psychiatry Res. 2005;138(3):133–42.
5. Kubera KM, Sambataro F, Vasic N, Wolf ND, Frasch K, Hirjak D, et al. Source-based morphometry analysis of grey matter volume reduction in schizophrenia patients with auditory hallucinations. Neuropsychobiology. 2010;61(1):1–9.
6. McCarty-Jones S, Thomas N, Strauss C, Dodgson G, Jones N, Woods A, et al. Better than mermaids and stray dogs? Subtyping auditory verbal hallucinations and its implications for research and practice. Schizophr Bull. 2014;40 Suppl 4:S257–84.
7. Castella NG, Gemen GJ, Feldstein SC, Sawa A, Schretlen DJ. The insula-claustrum region and delusions in schizophrenia. Schizophr Res. 2013;133(1–3):177–81.
8. Weiland BJ, Korycin斯基 ST, Soules M, Zublila JK, Zucker RA, HeitzeG WM. Substance abuse risk in emerging adults associated with smaller frontal gray matter volumes and higher externalizing behaviors. Drug Alcohol Depend. 2014;137:68–75.
9. Arango C, Rapado-Castro M, Reig S, Castro-Fornieles J, Gonzalez-Pinto A, Otero S, et al. Progressive brain changes in children and adolescents with first-episode psychosis. Arch Gen Psychiatry. 2012;69(1):16–26.
10. Andreasen NC, Nopoulos P, Magnotta V, Pierson R, Ziebell S, Ho BC. Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia. Biol Psychiatry. 2011;70(7):62–9.
11. Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev. 2013;37(8):1680–91.
12. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-I/P). New York (NY): Biometrics Research Department: New York State Psychiatric Institute; 1996.
13. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-Patient Edition (SCID-I-NP). New York (NY): Biometrics Research, New York State Psychiatric Institute; 2002.
14. Gong YX. Revision of Wechsler's Adult Intelligence Scale in China. Acta Psychologica Sinica. 1983;15(3):362–70.
15. Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa; 1984b.
16. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa; 1984a.
17. Hoffman RE, Hawkins KA, Gueorguieva R, Boutros NN, Rachid F, Carroll K, et al. Transcranial magnetic stimulation of left temporo-parietal cortex and medication-resistant auditory hallucinations. Arch Gen Psychiatry. 2003;60(1):49–56.
18. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64(6):663–7.
19. Annett M. A classification of hand preference by association analysis. Br J Psychol. 1970;61(3):303–21.
20. Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage. 2012;61(4):1402–18.
21. Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A. 2000;97(20):10500–5.
22. Desikan RS, Segonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31(3):968–80.
23. Sprooten E, Papmeyer M, Smyth AM, Vincenzo D, Honold S, Conlon GA, et al. Cortical thickness in first-episode schizophrenia patients and individuals at high familial risk: a cross-sectional comparison. Schizophr Res. 2013;151(1–3):3259–64.
24. Li G, Wang L, Shi F, Lyall AE, Amin M, Peng Z, et al. Cortical thickness and surface area in neonates at high risk for schizophrenia. Brain Struct Funct. 2014 (Epub ahead of print).
25. van Haren NE, Schnack HG, Cahn W, van den Heuvel MP, Lepage C, Collins L, et al. Changes in cortical thickness during the course of illness in schizophrenia. Arch Gen Psychiatry. 2011;68(9):871–80.
26. Oelt Knoche V, Knochel C, Rotarska-Jagiela A, Reinek B, Pruvo D, Haenschel C, et al. Association between psychotic symptoms and cortical thickness reduction across the schizophrenia spectrum. Cereb Cortex. 2013;23(1):161–70.
37. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry. 2005;62(4):361–70.

38. Smieskova R, Fusar-Poli P, Allen P, Bendfeldt K, Stieglitz RD, Drewe J, et al. The effects of antipsychotics on the brain: what have we learnt from structural imaging of schizophrenia?–a systematic review. Curr Pharm Des. 2009;15(22):2535–49.

39. Hajjmi SV, Van Haren N, Cahn W, Koolschijn PC, Hulshoff Pol HE, Kahn RS. Brain volumes in schizophrenia: a meta-analysis in over 18,000 subjects. Schizophr Bull. 2013;39(5):1129–38.

40. Schultz CC, Koch K, Wagner G, Reebel M, Schachtzabel C, Gaser C, et al. Reduced cortical thickness in first-episode schizophrenia. Schizophr Res. 2010;116(2–3):204–9.

41. Parent AC, Malcolm B. Carpenter’s human neuroanatomy, 9th ed./André Parent. edn: Baltimore: Williams & Wilkins; 1996; 1996.

42. Liegeois-Chauvel C, Musolino A, Chauvel P. Localization of the primary auditory area in man. Brain. 1991;114(Pt 1A):139–51.

43. Douaud G, Smith S, Jenkinson M, Behrens T, Johansen-Berg H, Vickers J, et al. Anatomically related grey and white matter abnormalities in adolescent-onset schizophrenia. Brain. 2007;130(Pt 9):2375–86.

44. Byun MS, Kim JS, Jung WH, Jang JH, Choi JS, Kim SN, et al. Regional cortical thinning in subjects with high genetic loading for schizophrenia. Schizophr Res. 2012;141(2–3):197–203.

45. van Swam C, Federspiel A, Hubil D, Wiest R, Boesch C, Vormathen P, et al. Possible dysregulation of cortical plasticity in auditory verbal hallucinations: a cortical thickness study in schizophrenia. J Psychiatr Res. 2012;46(8):1015–23.

46. Kompus K, Falkenberg LE, Bless JJ, Johnsen E, Kroken RA, Krausvik B, et al. The role of the primary auditory cortex in the neural mechanism of auditory verbal hallucinations. Front Hum Neurosci. 2013;7:144.

47. Palaniyappan L, Balain V, Radua J, Liddle PF. Structural correlates of auditory hallucinations in schizophrenia: a meta-analysis. Schizophr Res. 2012;137(1–3):169–73.

48. Selemon LD, Goldman-Rakic PS. The reduced neuropil hypothesis: a circuit-based model of schizophrenia. Biol Psychiatry. 1999;45(1):17–25.

49. Sun D, Stuart GW, Jenkinson M, Wood SJ, McGorry PD, Velakoulis D, et al. Brain surface contraction mapped in first-episode schizophrenia: a longitudinal magnetic resonance imaging study. Mol Psychiatry. 2009;14(8):876–86.

50. Tomelleri L, Jogi J, Perlini C, Bellani M, Ferro A, Rambaldelli G, et al. Brain structural changes associated with chronicity and antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol. 2009;19(12):835–40.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit